ArticleJSES international2025
Incidence, management, and outcomes following elbow ulnar collateral ligament injuries in nonquarterback professional football players.
Article in JSES international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ulnar collateral ligament (UCL) injuries can cause significant disability, especially in overhead throwing athletes. A majority of studies in the literature focus on the effects of UCL injuries in baseball players, but little is known about the severity and outcomes of these injuries in elite nonthrowing contact athletes. The purpose of this study was to characterize the severity of UCL injuries and describe management outcomes in nonthrowing professional football players. Methods: A retrospective review was conducted using the National Football League (NFL) Injury Surveillance System on nonquarterback players that had a UCL injury from 2015 to 2022. Player demographics, player position, severity and mechanism of injury, type of management, and time to return to play were collected. The severity of injury was classified based on laxity on clinical examination and graded on a scale of I-III. Data were analyzed to determine the number of injuries that occurred per year, per position, and per setting to determine differences in time from play that was missed based on injury severity. Statistical significance was set a Results: A total of 268 nonquarterback NFL players sustained isolated UCL injuries between 2015 and 2022, including 33.5 ± 4.2 injuries per year. Offensive and defensive linemen were the most common positions to sustain isolated UCL injuries, accounting for 56.0% (150 of 268 total injuries total) of all nonquarterback UCL injuries in the NFL. Ninety-eight percent of player with isolated UCL injuries were treated nonoperatively with only 4 players requiring surgical treatment of their injury. Seventy-three percent of injuries were grade I sprains, 16.8% were grade II sprains, and 10.1% were Grade III sprains. Seventy-two percent of athletes did not miss any time due to their isolated UCL injury. In the 28% of players that did miss time, the mean time missed was 5.4 ± 24.2 days. There was a significant difference in the time missed between grade I and grade II injuries (1.1 days vs. 12.4 days; Conclusion: Isolated UCL injuries are relatively uncommon injuries in nonquarterback NFL players. The vast majority of injuries are grade I sprains and are treated nonoperatively. Grade II and grade III injuries result in significantly increased time missed compared to grade I injuries. This information can be useful when counseling players regarding prognosis and timing of return to play based on severity of injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.